A different substance entirely: Mislabeled products are rampant in the unregulated market
The result is expert guidance, sustainable progress, and support that fits your life.
Following the positive REDEFINE 1 Phase 3 data (published June 2025, PMID: 40544433), Novo Nordisk announced plans to file regulatory applications for CagriSema for obesity in the United States (FDA), European Union (EMA), and other major markets in 20252026
Our team understands it can be difficult to slim down on your own, and we are excited to partner with you on your weight loss journey!
Caveats: Real-world safety data, payer adoption, and long-term remission outcomes will determine how quickly this approach reshapes clinical practice
The individual in the photo is not the individual who provided this testimonial.